Home Schedule Guidelines & Outline Syllabus & Reading Materials Topics Course Preceptors Contact Preceptors Contact Course Leaders
Syllabus & Reading Materials Syllabus & Reading Materials | Fall 2025 Date Faculty Preceptor Assigned Reading Friday, September 5 Ali Naji, MD, PhD Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead Monday, September 8 Sneha Narasimhan, MD, PhD Anti-amyloid antibody therapies in Alzheimer’s disease Anti‑Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease Biogen’s Aduhelm controversy as a case study for accelerated approval biomarkers in Alzheimer’s and related diseases Wednesday, September 17 Carl June, MD Monday, September 29 Kathy High, MD Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study Monday, October 6 Peter Lebowitz, MD, PhD Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer TAR-210 Erdafitinib Intravesical Delivery System in Non–Muscle-Invasive Bladder Cancer With Select FGFRAlterations: Updated First-in-Human Results Wednesday, October 15 Jake Brenner, MD, PhD Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids Multi-stage-mixing to control the supramolecular structure of lipid nanoparticles, thereby creating 4 a core-then-shell arrangement that improves performance by orders of magnitude Targeting DNA-LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity Monday, October 20 Paul Offit, MD Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood CHOP - Vaccine Ingredients: Aluminum Friday, November 7 Drew Weissman, MD, PhD Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease A Milestone for Gene-Editing Therapies Monday, November 10 Christina Coughlin, MD, PhD Monday, November 17 Tal Zaks, MD, PhD Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer A neoantigen vaccine generates antitumour immunity in renal cell carcinoma Top
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Report Accessibility Issues and Get Help | Privacy Policy | Site Design: PMACS Web Team.